omniture
logo
Search
礼邦医药
Media Room

Latest News

rss

Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffecti...

2025-11-07 20:00 1148
Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund...

2025-06-26 20:00 1805

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals

2025-01-07 21:00 1975

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SHANGHAI, March 29, 2024 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebun...

2024-03-29 20:00 2287

Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund...

2023-12-13 21:00 2000